Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Checkpoint inhibitors show promise as second-line salvage therapy in advanced Hodgkin lymphoma, per Philippe Armand, MD, PhD
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Andrew M. Evens, DO, MBA, MSc, shared practice-changing studies in Hodgkin lymphoma and what to expect in 2025.
A study found maximum tumor diameter and lack of radiotherapy with chemotherapy are independent risk factors for HL relapse.
FDG-PET response-guided salvage may identify which pediatric patients achieve excellent outcomes without transplant.
Challenges exist in translating individual patients' risk into risk groups for use in everyday practice or a trial's design.
A phase 2 study sought to determine if use of nivolumab instead of vinblastine in the test combination improved safety.
BrECADD showed better tolerability and efficacy than eBEACOPP for the treatment of advanced-stage classical Hodgkin lymphoma.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Robert Stuver, MDRobert Stuver is a hematologist-oncologist at Memorial Sloan Kettering Cancer Center
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.